ArticleAdvances in experimental medicine and biology2021
Magnetic Resonance Imaging for Drug Development.
Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the merit of high-resolution cross-sectional imaging, magnetic resonance imaging (MRI) has been utilized in many preclinical and clinical research fields. In addition to T2-weighted imaging for assessing anatomic changes by disease and therapeutic agents, diffusion-weighted imaging, dynamic contrast-enhanced MRI, and MR spectroscopy can provide disease- and drug-specific functional information in both in vivo and ex vivo status. Another advantage of MRI is its ability to bridge the preclinical and clinical experiments as it allows similar study methods and environments between animals and humans. Therefore, MRI can be used as a useful tool for drug development. Investigators have discovered a variety of MRI biomarkers that can quantitatively measure the biological alteration led by disease and treatment. In this chapter, a number of commonly used preclinical MRI biomarkers for drug development will be introduced and discussed, particularly being focused on their value for translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.